Skip to main content
. 2020 Jan 27;64(2):e01729-19. doi: 10.1128/AAC.01729-19

FIG 3.

FIG 3

Three-dimensional surface plots showing the interaction between maraviroc (MVC) and tenofovir (TFV) (a) and MVC and emtricitabine (FTC) (b). The combinations fit the surface of the model predictions well, without any bias.